PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2

Abstract The rapid development of safe and effective vaccines against SARS CoV-2 is the need of the hour for the coronavirus outbreak. Here, we have developed PRAK-03202, the world’s first triple antigen VLP vaccine candidate in a highly characterized S. cerevisiae-based D-CryptTM platform, which in...

Full description

Saved in:
Bibliographic Details
Published in:bioRxiv 2020-10
Main Authors: Mazumder, Saumyabrata, Rastogi, Ruchir, Undale, Avinash, Arora, Kajal, Nupur Mehrotra Arora, Pratim, Biswa, Kumar, Dilip, Abyson, Joseph, Mali, Bhupesh, Arya, Vidya Bhushan, Kalyanaraman, Sriganesh, Mukherjee, Abhishek, Gupta, Aditi, Potdar, Swaroop, Sourav Singha Roy, Parashar, Deepak, Paliwal, Jeny, Singh, Sudhir Kumar, Naqvi, Aelia, Srivastava, Apoorva, Singh, Manglesh Kumar, Kumar, Devanand, Bansal, Sarthi, Rautray, Satabdi, Singh, Indrajeet, Fengade, Pankaj, Kumar, Bibekanand, Saini, Manish, Jain, Kshipra, Gupta, Reeshu, Kundu, Prabuddha Kumar
Format: Article
Language:English
Subjects:
Antigens
Coronaviruses
Epitopes
Immune response
Immune response (cell-mediated)
Immune response (humoral)
Immunization
Immunology
Lymphocytes T
Membrane proteins
Vaccines
γ-Interferon
Citations: Items that this one cites
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The rapid development of safe and effective vaccines against SARS CoV-2 is the need of the hour for the coronavirus outbreak. Here, we have developed PRAK-03202, the world’s first triple antigen VLP vaccine candidate in a highly characterized S. cerevisiae-based D-CryptTM platform, which induced SARS CoV-2 specific neutralizing antibodies in BALB/c mice. Immunizations using three different doses of PRAK-03202 induces antigen specific (Spike, envelope and membrane proteins) humoral response and neutralizing potential. PBMCs from convalescent patients, when exposed to PRAK-03202, showed lymphocyte proliferation and elevated IFN-γ levels suggestive of conservation of epitopes and induction of T helper 1 (Th1)–biased cellular immune responses. These data support the clinical development and testing of PRAK-03202 for use in humans. Competing Interest Statement The authors have declared no competing interest.
ISSN:2692-8205
DOI:10.1101/2020.10.30.360115